HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO's HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications preselected by HiFiBiO's proprietary Drug Intelligence Science (DIS) platform. HFB200301 is currently being evaluated as a single agent in the first-in-human dose escalation and expansion clinical trial (NCT05238883), with the intention of following up with a combination of HFB200301 and tislelizumab.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.97 CHF | -1.01% | -1.71% | +3.65% |
05-02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
05-02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.65% | 198B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors